Sadeque S Naficy

48290556, May 9, 1989

Jan 23, 1987

7/006478

Sadeque S. Naficy - Houston TX

A61K 31505
A61K 3150

514 43

A method of treatment is disclosed for herpes infections of external tissues and method of preventing the occurrence of blisters and ulcerations in herpes disease in humans. The method consists of directly injecting small treatment amounts of suitable antiviral agents, e. g. , acyclovir, ribavirin, or vidarabine (ara-A), within the specific time period of first 36 hours after the appearance of detectable manifestations of external-tissue infection or any of the prodromal symptoms of burning pain, itching, tingling, swelling and erythema or combinations thereof. The treatment amounts of antiviral drugs per day used in this invention are very small compared to the dosage amounts used by prior art calculated based on kilograms of body weight per day. The antiviral drugs so injected will kill the virus quickly in the skin or mucus membrane, or inhibit its replication or otherwise render the virus inactive before the virus will have time to multiply and form the blisters and ulcerations.

54197597, May 30, 1995

May 27, 1993

8/068510

Sadeque S. Naficy - Houston TX

A61M 114

604 5

An extracorporeal apparatus and methods for treatment of HIV (Human Immuno-deficiency Virus) infections and AIDS. Infected blood is drawn from a patient and separated into infected components (comprising plasma, cell-free virus, and infected white cells containing replicating virus) and uninfected components (comprising red cells and platelets). The uninfected components are returned to the patient and the infected components are treated with organic agents. The preferred organic agent is diethyl ether which is used in an amount and over a period of time sufficient to kill the infected cells and the cell-free virus. The preferred apparatus functions at temperatures below 56. degree. C. , and includes centrifugal separators for separating the infected components from healthy components; mixers and agitators inside an air-tight chamber void of oxygen where the infected components are mixed and treated with ether; centrifuges and distillators working under vacuum which remove the ether after the completion of treatment; a gas chromatograph with automatic sampling for determining the residues of ether and the safety of the treated components; and mechanisms for returning the treated and safe components, in conjunction with intravenous fluids, separately or together with the healthy components, to the patient. The treatment cycle is repeated until the patient's blood is made free of virus.

42989981, Nov 10, 1981

Dec 8, 1980

6/214449

Sadeque S. Naficy - Houston TX

A61F 124

3 36

A newly developed breast prosthesis overcomes the tightness and contracture of the fibrous capsule which forms around the existing prosthesis. The unique construction of the new prosthesis causes the capsule to form at a predetermined, controlled distance from the surface thereof. This prosthesis is constructed with a first phase or outer temporary component and a second phase or inner permanent component. The inner component is a container or sac of a flexible, non-absorbable material filled with a fluid or gel filler material. The temporary outer component is an outer container or cover of a material which is absorbable under the conditions of use, and an inert filler material, preferably an absorbable, biologically acceptable liquid, e. g. saline solution, filling the space between the inner and outer components. The inner component is preferably of silicone rubber film and is filled with a silicone gel.

54843960, Jan 16, 1996

Nov 17, 1988

7/272535

Sadeque S. Naficy - Houston TX

A61M 100

604 4

A method and device are disclosed for treatment of HIV (Human Immuno-deficiency virus) infections and AIDS. The method consists of separating the blood, in an extracorporeal device, into an infected component and a healthy component. The healthy component including red cells and platelets is returned to the patient. The infected component, consisting of infected plasma with cell-free virus and infected white cells containing replicating virus, is treated with organic solvents. In the preferred embodiment the organic solvent used is diethyl ether. The ether will dissolve the lipid-containing envelope of the cell-free virus and will subsequently kill the virus. The ether will also kill the infected cells containing replicating virus, thus it will stop the maturation and budding of the virus which would otherwise occur at the cell-membrane. Diethyl ether which is highly volatile and has a boiling point of only 34. 43. degree. C. is then removed from the treated blood or plasma by distillation under vacuum at temperatures below 56. degree. C.

44280823, Jan 31, 1984

Nov 5, 1981

6/318582

Sadeque S. Naficy - Houston TX

A41C 310

3 36

A newly developed breast prosthesis overcomes the tightness and contracture of the fibrous capsule which forms around the existing prostheses. This prosthesis is constructed with an outer temporary component and an inner permanent component. The inner component is a fluid- or gel-filled container or sac of a flexible, non-absorbable material. The temporary outer component is a container or cover of a material which is absorbable under the conditions of use, and an inert filler material, preferably an absorbable, biologically acceptable liquid, e. g. saline solution, filling the space between the inner and outer components which is added through a valve or tube in the outer cover either at the time of manufacture or at the time of implantation. The inner component is preferably of silicone rubber film and is filled with a silicone gel. The outer portion is in the form of a sheet, film or coating of a material which can be absorbed in the body after surgical implantation.